State Street’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,645,236
| Closed | -$79M | – | 3931 |
|
|
2020
Q1 | $79M | Buy |
1,645,236
+8,295
| +0.5% | +$386K | 0.01% | 972 |
|
|
2019
Q4 | $76.8M | Sell |
1,636,941
-8,428
| -0.5% | -$373K | 0.01% | 1225 |
|
|
2019
Q3 | $38.9M | Buy |
1,645,369
+142,218
| +9% | +$4.21M | ﹤0.01% | 1614 |
|
|
2019
Q2 | $45.2M | Buy |
1,503,151
+568,075
| +61% | +$13M | ﹤0.01% | 1548 |
|
|
2019
Q1 | $20.9M | Buy |
935,076
+700,975
| +299% | +$15.1M | ﹤0.01% | 2007 |
|
|
2018
Q4 | $4.26M | Buy |
234,101
+28,269
| +14% | +$444K | ﹤0.01% | 2801 |
|
|
2018
Q3 | $3.73M | Buy |
205,832
+18,717
| +10% | +$222K | ﹤0.01% | 2999 |
|
|
2018
Q2 | $1.86M | Sell |
187,115
-134
| -0.1% | -$925 | ﹤0.01% | 3296 |
|
|
2018
Q1 | $997K | Buy |
187,249
+28,476
| +18% | +$204K | ﹤0.01% | 3340 |
|
|
2017
Q4 | $1.35M | Buy |
158,773
+3,251
| +2% | +$40K | ﹤0.01% | 3295 |
|
|
2017
Q3 | $2.27M | Buy |
155,522
+4,459
| +3% | +$67.4K | ﹤0.01% | 3150 |
|
|
2017
Q2 | $2.83M | Buy |
151,063
+43,376
| +40% | +$979K | ﹤0.01% | 2995 |
|
|
2017
Q1 | $2.29M | Buy |
107,687
+37,999
| +55% | +$727K | ﹤0.01% | 3031 |
|
|
2016
Q4 | $1.06M | Buy |
+69,688
| New | +$947K | ﹤0.01% | 3264 |
|
Other funds holding RARX
State Street's RARX Position: Q2 2020 in Review
State Street sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,645,236 shares — an estimated $79M sold.
State Street first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $79M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- State Street reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- State Street sold 1,645,236 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $79M.
- State Street first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- State Street's Ra Pharmaceuticals, Inc. Common Stock position peaked at $79M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on State Street's 13F filing for Q2 2020, filed 14 Aug 2020.